Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
NCT07082816Phase 3Completed
- Lead sponsor
- Alcon Research (Industry)
- Enrollment
- 489 (actual)
- Start date
- 2 Sep 2025
- Primary completion
- 6 Apr 2026 (actual)
- Study completion
- 6 Apr 2026
- Last update posted
- 21 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution Drug
- Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution Drug
Conditions and primary outcome
- Ocular Hypertension
- Open Angle Glaucoma
Primary outcome
Mean Intraocular Pressure at each timepoint post-randomization (Week 2, Week 6, Month 3 at 08:00, 10:00, 16:00 hours)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07082816.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07082816 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.